Herwandhani Putri

513 total citations
39 papers, 408 citations indexed

About

Herwandhani Putri is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Herwandhani Putri has authored 39 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 11 papers in Pharmacology and 8 papers in Oncology. Recurrent topics in Herwandhani Putri's work include Biological Stains and Phytochemicals (6 papers), Computational Drug Discovery Methods (6 papers) and Cancer Mechanisms and Therapy (5 papers). Herwandhani Putri is often cited by papers focused on Biological Stains and Phytochemicals (6 papers), Computational Drug Discovery Methods (6 papers) and Cancer Mechanisms and Therapy (5 papers). Herwandhani Putri collaborates with scholars based in Indonesia, United States and Japan. Herwandhani Putri's co-authors include Adam Hermawan, Riris Istighfari Jenie, Muthi Ikawati, Edy Meiyanto, Rohmad Yudi Utomo, Yonika Arum Larasati, Masashi Kawaichi, Jun‐ya Kato, Noriko Yoneda‐Kato and Ikuko Nakamae and has published in prestigious journals such as SHILAP Revista de lepidopterología, The International Journal of Biochemistry & Cell Biology and Frontiers in Oncology.

In The Last Decade

Herwandhani Putri

37 papers receiving 401 citations

Peers

Herwandhani Putri
Nazia Afroze Saudi Arabia
Wafaa S. Ramadan United Arab Emirates
Yun-Sil Lee South Korea
Jeong‐Geon Mun South Korea
Rıza Serttas Türkiye
Samia S. Messeha United States
Ritu Raina Saudi Arabia
Herwandhani Putri
Citations per year, relative to Herwandhani Putri Herwandhani Putri (= 1×) peers Madhumitha Kedhari Sundaram

Countries citing papers authored by Herwandhani Putri

Since Specialization
Citations

This map shows the geographic impact of Herwandhani Putri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herwandhani Putri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herwandhani Putri more than expected).

Fields of papers citing papers by Herwandhani Putri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herwandhani Putri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herwandhani Putri. The network helps show where Herwandhani Putri may publish in the future.

Co-authorship network of co-authors of Herwandhani Putri

This figure shows the co-authorship network connecting the top 25 collaborators of Herwandhani Putri. A scholar is included among the top collaborators of Herwandhani Putri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herwandhani Putri. Herwandhani Putri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hermawan, Adam & Herwandhani Putri. (2025). Bioinformatics Analysis of Programmed Death-1–Trastuzumab Resistance Regulatory Networks in Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention. 26(1). 279–292.
2.
3.
Hermawan, Adam & Herwandhani Putri. (2023). Characterizing excision repair cross-complementing family genes as drug resistance biomarkers in breast cancer. Beni-Suef University Journal of Basic and Applied Sciences. 12(1). 2 indexed citations
4.
Hermawan, Adam & Herwandhani Putri. (2023). Bioinformatics Analysis of the Genetic and Epigenetic Alterations of Bone Morphogenetic Protein Receptors in Metastatic Breast Cancer. Biochemical Genetics. 62(2). 594–620. 2 indexed citations
5.
Hermawan, Adam, et al.. (2022). Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen. Frontiers in Oncology. 12. 1019025–1019025. 6 indexed citations
6.
Hermawan, Adam & Herwandhani Putri. (2022). Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy. BMC Genomic Data. 23(1). 72–72. 6 indexed citations
7.
Hermawan, Adam & Herwandhani Putri. (2021). Bioinformatics Analysis of TIMP1, HK2 and IGFBP7 as Potential Biomarkers and Therapeutic Targets of Paclitaxel Resistance in Breast Cancer. SHILAP Revista de lepidopterología. 4 indexed citations
8.
Hermawan, Adam & Herwandhani Putri. (2021). Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab. Saudi Pharmaceutical Journal. 29(11). 1289–1302. 3 indexed citations
9.
Hermawan, Adam & Herwandhani Putri. (2020). Integrative bioinformatics analysis reveals miR-494 and its target genes as predictive biomarkers of trastuzumab-resistant breast cancer. Journal of the Egyptian National Cancer Institute. 32(1). 16–16. 7 indexed citations
10.
Hermawan, Adam, Herwandhani Putri, & Rohmad Yudi Utomo. (2020). Functional network analysis reveals potential repurposing of β-blocker atenolol for pancreatic cancer therapy. DARU Journal of Pharmaceutical Sciences. 28(2). 685–699. 7 indexed citations
11.
Hermawan, Adam & Herwandhani Putri. (2020). Integrative Bioinformatics Analysis Reveals Potential Target Genes and TNFα Signaling Inhibition by Brazilin in Metastatic Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention. 21(9). 2751–2762. 8 indexed citations
12.
Meiyanto, Edy, Herwandhani Putri, Yonika Arum Larasati, et al.. (2020). The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells. Advanced Pharmaceutical Bulletin. 11(1). 188–196. 25 indexed citations
13.
Hermawan, Adam & Herwandhani Putri. (2020). Identification of potential gene associated with berberine in overcoming tamoxifen resistance by functional network analysis. Journal of Applied Pharmaceutical Science. 5 indexed citations
14.
Hermawan, Adam, Herwandhani Putri, & Rohmad Yudi Utomo. (2019). Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. Molecular Diversity. 24(4). 933–947. 26 indexed citations
15.
Hermawan, Adam & Herwandhani Putri. (2019). Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer. SHILAP Revista de lepidopterología. 24(2). 65–65. 2 indexed citations
16.
Hermawan, Adam & Herwandhani Putri. (2018). Current report of natural product development against breast cancer stem cells. The International Journal of Biochemistry & Cell Biology. 104. 114–132. 34 indexed citations
17.
Utomo, Rohmad Yudi, et al.. (2017). SYNTHESIS AND CYTOTOXIC ACTIVITY OF 2,5-BIS(4-BORONIC ACID)BENZYLIDINE CYCLOPENTANONE ON HER2 OVEREXPRESSED-CANCER CELLS. INDONESIAN JOURNAL OF PHARMACY. 28(2). 74–74. 14 indexed citations
18.
Putri, Herwandhani, et al.. (2016). Ethanolic Leaves Extract of Awar-awar (Ficus Septica) as Selective Chemopreventive Agent on Various Cancer Cells. 1(2). 190–197. 3 indexed citations
19.
Putri, Herwandhani, et al.. (2016). Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells.. PubMed. 17(5). 2683–8. 15 indexed citations
20.
Putri, Herwandhani, et al.. (1970). The Selectivity of Ethanolic Extract of Buah Makassar (Brucea javanica) on Metastatic Breast Cancer Cells. 2(1). 1–1. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026